Review about proteomics for MS biomarkers

[frodo]

Proteomic approaches to decipher mechanisms underlying pathogenesis in MS

Full PDF:

https://onlinelibrary.wiley.com/doi/epd ... .201800335


Conclusion

Proteomic analysis of CNS tissue and body fluids is a powerful technique to identify biomarkers and therapeutic candidates. Over the past several years, advancements in the field of proteomic research have been instrumental in identifying new biomarkers in MS disease like CHI3L1, Tymosin β4, SCGs etc. However, validation and application of these markers is yet to be conducted in new cases using different techniques.

Despite this, proteomic analysis application in the field of MS is still lagging behind than other omics techniques, although many studies have reported correlations with several potential candidates. One of the main reasons hindering application of this technique in detecting biomarkers of disease progression or pathogenesis is the complexity of the disease itself. MS affects both the CNS and immune system, making it extremely difficult to detect underlying pathogenic mechanisms. It is therefore expected that MS will not have a single biomarker, but rather a combination of several candidates that reflect the pathogenesis to its full extent.

Designing of experiments that target each of the components of the disease is needed. In addition, modern techniques of cell separation and proteomic advancements must be used to determine the cellular targets that are indicative of each of these disease components. Moreover, there is an urgent need for development of biomarkers that reflect the repair mechanisms in MS. As we enter into the new era of MS therapeutics directed at repair, these markers can be used for validation of therapeutic candidates.